Role of Immunotherapy in Thymic Malignancies Presented By Heather Wakelee at 2019 ASCO Annual Meeting.

Presentación del tema: "Role of Immunotherapy in Thymic Malignancies Presented By Heather Wakelee at 2019 ASCO Annual Meeting."— Transcripción de la presentación:

1 Role of Immunotherapy in Thymic Malignancies Presented By Heather Wakelee at 2019 ASCO Annual Meeting

2 Disclosures Presented By Heather Wakelee at 2019 ASCO Annual Meeting

3 Overview Presented By Heather Wakelee at 2019 ASCO Annual Meeting

4 Slide 4 Presented By Heather Wakelee at 2019 ASCO Annual Meeting

5 Slide 5 Presented By Heather Wakelee at 2019 ASCO Annual Meeting

6 Slide 6 Presented By Heather Wakelee at 2019 ASCO Annual Meeting

7 Autoimmunity in TETs Presented By Heather Wakelee at 2019 ASCO Annual Meeting

8 Autoimmunity in thymic malignancies Presented By Heather Wakelee at 2019 ASCO Annual Meeting

9 1st line Case Presented By Heather Wakelee at 2019 ASCO Annual Meeting

10 Chemotherapy – 1st line Presented By Heather Wakelee at 2019 ASCO Annual Meeting

11 Anthracycline regimens- RR 51-100% Presented By Heather Wakelee at 2019 ASCO Annual Meeting

12 2nd line Case Presented By Heather Wakelee at 2019 ASCO Annual Meeting

13 Active Agents in TETs Presented By Heather Wakelee at 2019 ASCO Annual Meeting

14 Positive “Targeted Drug Trials” Presented By Heather Wakelee at 2019 ASCO Annual Meeting

15 Other novel combinations Presented By Heather Wakelee at 2019 ASCO Annual Meeting

16 Rhythmic TET Presented By Heather Wakelee at 2019 ASCO Annual Meeting

17 Slide 17 Presented By Heather Wakelee at 2019 ASCO Annual Meeting

18 Some ongoing trials Presented By Heather Wakelee at 2019 ASCO Annual Meeting

19 Immunotherapy in TC Presented By Heather Wakelee at 2019 ASCO Annual Meeting

20 PD-L1 score and histology correlation Presented By Heather Wakelee at 2019 ASCO Annual Meeting

21 Slide 21 Presented By Heather Wakelee at 2019 ASCO Annual Meeting

22 Avelumab: Phase I (Javelin Solid Tumor) Presented By Heather Wakelee at 2019 ASCO Annual Meeting

23 Prospective Trial all TETs with Pembrolizumab (200 mg q 3 wks) Presented By Heather Wakelee at 2019 ASCO Annual Meeting

24 Is it worth the risk? Presented By Heather Wakelee at 2019 ASCO Annual Meeting

25 Slide 25 Presented By Heather Wakelee at 2019 ASCO Annual Meeting

26 Pembrolizumab Toxicity Presented By Heather Wakelee at 2019 ASCO Annual Meeting

27 PD-L1 expression and Pembrolizumab Activity Presented By Heather Wakelee at 2019 ASCO Annual Meeting

28 Other Biomarkers Presented By Heather Wakelee at 2019 ASCO Annual Meeting

29 Ongoing IO Clinical Trials in TETs Presented By Heather Wakelee at 2019 ASCO Annual Meeting

30 Conclusions Presented By Heather Wakelee at 2019 ASCO Annual Meeting